Preclinical antisense biotech, led by former Sarepta CEO Kaye, vaults on to Nasdaq with upsized IPO
Less than a year after raising $90 million in its second round of financing, former Sarepta chief Edward Kaye is making the leap to the Nasdaq on Wednesday with an upsized offering for his preclinical antisense biotech, Stoke Therapeutics.
The company in-licensed its technology: Targeted Augmentation of Nuclear Gene Output (TANGO) from Cold Spring Harbor Laboratory’s Adrian Krainer, who is credited as the inventor of Biogen’s $BIIB spinal muscular atrophy drug Spinraza. Krainer co-founded Stoke and serves on its board.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.